Premium
ENTERIC‐COATED L‐DOPA (PRODOPA) A NEW APPROACH TO L‐DOPA THERAPY IN PARKINSON'S DISEASE
Author(s) -
GILLIGAN BERNARD,
HANCOCK RICHARD
Publication year - 1975
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1975.tb106351.x
Subject(s) - parkinson's disease , levodopa , medicine , enteric coated , enteric nervous system , disease , gastroenterology
Seventeen patients treated for a mean period of 9 4 months with an enteric‐coated form of L‐dopa (Prodopa), obtained the usual spectrum of benefit as from conventional L‐dopa. There was a significant dose‐sparing effect with the use of the enteric‐coated preparation of the order of 40% to 50%, whilst reducing gastrointestinal side effects to a minimum, at the same time as achieving optimal clinical benefit. Enteric‐coated L‐dopa appears to be a useful and welcome addition to the therapeutic armamentarium for Parkinson's disease.